Adverse reactions among patients being treated for multi-drug resistant tuberculosis in Egypt from July 2006 to January 2009

Eldin, Mohamed Awad Tag; Halim, Hesham A Abdel; El-Tantawy, Aboda Mahmoud

doi:10.1016/j.ejcdt.2015.05.011

Cited by 13 publications

(13 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second-line injectable agents including aminoglycosides (amikacin, kanamycin, streptomycin), and mechanistically related polypeptide drug (capreomycin) in combination with fluoroquinolones, form the backbone for the treatment of multidrug-resistant tuberculosis, and also recommended by the earlier WHO guidelines [7]. A crucial issue related to long-term administration of the injectable group is its toxicity which affects adherence and treatment outcomes [8]. Nephrotoxicity and ototoxicity and are well known dose-related adverse effects of aminoglycosides and major concerns because of the narrow therapeutic range of these agents and the wide variability in pharmacokinetics among patients [9].…”

Section: Introductionmentioning

confidence: 99%

Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study

Shibeshi

Sheth

Admasu³

et al. 2019

BMC Pharmacol Toxicol

View full text Add to dashboard Cite

Background Nephrotoxicity and ototoxicity are clinically significant dose-related adverse effects associated with second-line anti-tubercular injectables drugs (aminoglycosides and capreomycin) used during intensive phase of treatment of multi-drug resistant tuberculosis (MDR-TB) patients. Data are scarce on injectable-induced nephrotoxicity and ototoxicity in Ethiopian MDR-TB patients. The aim of this study was to assess the prevalence, management of nephrotoxicity and ototoxic symptoms and treatment outcomes of patients treated for MDR-TB with injectable-based regimens. Method This was retrospective cohort study based on review of medical records of about 900 patients on MDR-TB treatment from January 2010 to December 2015 at two large TB referral hospitals in Addis Ababa, Ethiopia. Nephrotoxicity in study participants was screened using baseline and monthly measurement of serum creatinine and clinical diagnosis and patient reports. Results Overall, 473 (54.2%) of participants were male. Children accounted for 47 (5.5%) of cases and the mean age of participants was 32 ± 12.6 years with range of 2–75 years. The majority ( n = 788, 84.6%) of participants had past history of TB. The most commonly used injectable anti-TB drug was capreomycin ( n = 789, 84.7%), while kanamycin and amikacin were also used. There was a statistically significant increment (p<0.05) in the mean serum creatinine values from baseline throughout intensive phase of treatment with a 10–18% prevalence of nephrotoxicity. Based on clinical criteria, nephrotoxicity was detected in 62 (6.7%) and ototoxic symptoms were detected in 42 (4.8%) participants. Nephrotoxicity and ototoxic symptoms were clinically managed by modification of treatment regimens including dose and frequency of drug administration. Conclusion Nephrotoxicity and ototoxic symptoms were significant problems among patients on follow-up for MDR-TB treatment. Based on laboratory criteria (serum creatinine), nephrotoxicity remained significant adverse events throughout intensive phase of treatment, indicating close monitoring of patients for successful outcome is mandatory until countries adopt the recent injectable-free WHO guideline and under specific conditions.

show abstract

Section: Introductionmentioning

confidence: 99%

Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study

Shibeshi

Sheth

Admasu³

et al. 2019

BMC Pharmacol Toxicol

View full text Add to dashboard Cite

show abstract

“…Studies included in this review were reported from 19 countries which cover three continents (Africa, Asia and Europe) [Table 1]. Seventeen studies were reported from Asian [32,34–40,42–44,46,48,53,54,60,61], eight from African [41,45,47,49,50,55,57,58] and five from European [33,48,52,56,59] countries. We categorized Russia, Turkey and Ukraine under European countries category.…”

Section: Resultsmentioning

confidence: 99%

“…We categorized Russia, Turkey and Ukraine under European countries category. The majority of studies were reported from India (ten studies) [32,34–37,43,46,51,53,54] followed by South Africa (two studies) [41,47] and Egypt (two studies) [57,58].…”

Section: Resultsmentioning

confidence: 99%

Is hypothyroidism rare in multidrug resistance tuberculosis patients on treatment? A systematic review and meta-analysis

et al. 2019

View full text Add to dashboard Cite

Background Hypothyroidism is one of the adverse drug reactions that associated with Multidrug Resistant Tuberculosis (MDR-TB) medications. Extremely variable magnitude of hypothyroidism in MDR-TB patients has been reported from different parts of the world. However, there is no evidence that tried to estimate the pooled prevalence of hypothyroidism to confirm the rareness of hypothyroidism in MDR-TB patients on treatment. Therefore, we did a systematic review and meta-analysis to estimate the prevalence of hypothyroidism in MDR-TB patients on treatment, and to summarize the demographic and clinical characteristics of the patients. Methods We conducted a systematic review and meta-analysis on studies reported around the world on the prevalence of hypothyroidism in MDR-TB patients on treatment. We searched electronic databases: PubMed/Medline, EMBASE, CINAHL, Science Direct, Academic Search Complete and Google scholar for English language articles without limiting publication year. We also reviewed the bibliographies of relevant studies and conducted an electronic search for relevant conference abstracts. Eligible studies were cross-sectional and cohort studies that included at least five participants. We used a random-effects model to estimate the pooled prevalence of hypothyroidism. The registration number of this review study protocol is CRD42018109237. Results We included 30 studies and pooled data on a total of 6,241 MDR-TB patients. The crude prevalence of hypothyroidism was extremely heterogeneous. The pooled prevalence of hypothyroidism in MDR-TB patients on treatment was 17.0% (95% CI: 13.0–20.0). Ethionamide and para-aminosalicylic acid (PAS) were the most frequently reported drugs that associated with the occurrence of hypothyroidism. Conclusion This review revealed that hypothyroidism is not a rare adverse drug reaction in MDR-TB patients on treatment. Ethionamide and PAS were the most frequently reported drugs that associated with the occurrence of hypothyroidism. Screening of hypothyroidism in MDR-TB patients on treatment is important while targeting patients on Ethionamide and PAS based treatment regimen.

show abstract

“…The rationale MDR-TB treatment with several types of drugs will cause problems in drug potentiation, as well as side effects. The response of each individual is unpredictable, but treatment should not stop just because of fear of the reaction that arises (El-Din et al, 2015). The incidence rate of patients experiencing severe adverse events was 91.3% with line two antituberculosis drugs, and the percentage of side effects in the mild category was 84.2% (Reviono et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

Adverse drug reactions associated with successful treatment of multidrug-resistant tuberculosis patients in Cempaka Putih Islamic Hospital Central Jakarta

Kurniawan

Cartika

Aisyah³

2021

Pharm Educ

View full text Add to dashboard Cite

Introduction: Indonesia experiences Tuberculosis (TB) cases that are very complex and complicated, especially those dealing with Multi-Drug Resistance TB (MDR-TB). Its therapy using several types of drugs can cause several problems; one of them is an adverse drug reaction. Aim: To investigate the association between Adverse Drug Reactions (ADR) and the successful treatments of MDR-TB patients. Method: This was a retrospective study, the population in this study were all patients with medical and treatment records for MDR-TB. This sampling type is a purposive sampling technique. The statistical analysis used the chi-square test as the statistical test. Results: The significant correlation was between the incidence of ADRs and successful treatment with p=0.024; odd ratio=2.526; CI=1.193 - 17.892. Conclusions: This study may help in formulating strategies for the timely and aggressive management of adverse drug reactions. This can reduce the deferral of therapy and increase the clinical success rate.

show abstract

Adverse reactions among patients being treated for multi-drug resistant tuberculosis in Egypt from July 2006 to January 2009

Cited by 13 publications

References 15 publications

Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study

Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study

Is hypothyroidism rare in multidrug resistance tuberculosis patients on treatment? A systematic review and meta-analysis

Adverse drug reactions associated with successful treatment of multidrug-resistant tuberculosis patients in Cempaka Putih Islamic Hospital Central Jakarta

Contact Info

Product

Resources

About